Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart, Noemi

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. [electronic resource] - Lung cancer (Amsterdam, Netherlands) May 2014 - 161-7 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

1872-8332

10.1016/j.lungcan.2014.02.011 doi


Adenocarcinoma--drug therapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Carcinoma, Non-Small-Cell Lung--drug therapy
Disease Progression
Disease-Free Survival
Drug Administration Schedule
Drug Resistance, Neoplasm--genetics
Drug Synergism
ErbB Receptors--genetics
Erlotinib Hydrochloride
Female
Humans
Hydroxamic Acids--administration & dosage
Kaplan-Meier Estimate
Lung Neoplasms--drug therapy
Male
Middle Aged
Mutation, Missense
Quinazolines--administration & dosage
Treatment Outcome
Vorinostat